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167 Patients with cancer may report neuropsychiatric abnormalities including cognitive impairment, behavioral
18 disturbances, and psychiatric disorders that potentially worsen their quality of life, reduce their treatment response,
19 and aggravate their overall prognosis. Neuropsychiatric disturbances have a different pathophysiology, including
20 immuno-inflammatory and neuroendocrine mechanisms, as a consequence of oncologic treatments (chemo- and radio-
21 therapy). Among clinicians involved in the management of such patients, psychiatrists need to pay particular attention
22 in recognizing behavioral disturbances that arise in oncologic patients, and determining those that may be effectively
23 treated with psychotropic medications, psychotherapeutic interventions, and an integration of them. Through the
24 contribution of different clinicians actively involved in the management of oncological patients, the present review is
25 ultimately aimed at updating psychiatrists in relation to the pathophysiological mechanisms responsible for the onset of
26 cognitive, affective, and behavioral syndromes in these patients, along with epidemiologic and clinical considerations
27 and therapeutic perspectives.
28
29 Received 4 September 2017; Accepted 20 November 2017
30 Key words: Cognitive impairment, extracranial cancer, neuropathology, psychiatric symptoms, treatment.
31 Introduction
32 Before their clinical manifestations, tumors (arising
33 outside the brain and without direct diffusion to it) may
34 elicit changes of neuronal function. Additionally, when
35 facing a patient with clinically manifest cancer, the
36 clinician should remember that the disease might induce
37 distant effects due to nervous system involvement even
38 without direct invasion of the nervous tissue. Finally,
39 several drugs and other treatments used by oncologists
40 can impair brain functions.
41Tumor-related alterations cause cognitive, affective,
42and behavioral manifestations that can, in turn, influence
43the response of the patient to treatments and worsen the
44disease burden, ultimately increasing its social cost. Thus,
45the prompt recognition of tumor-related cognitive, affec-
46tive, and behavioral abnormalities is important for their
47appropriate management and treatment.
48Here, we review the clinical picture, pathophysiology,
49diagnosis, and management of the main tumor-related
50and treatment-related cognitive, affective, and beha-
51vioral syndromes in patients with cancer.
52Search Strategy
53References for this review were identified through
54searches of PubMed, Google Scholar, and MEDLINE
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55 without temporal and language limits, using the
56 following terms in combination: “adjustment disorder,”
57 “affective disorders,” “anxiety,” “behavior,” “behavioral
58 deficits,” “behavioral disorders,” “breast cancer,” “cancer
59 brain connectivity,” “cancer brain imaging,” “cancer brain
60 spectroscopy,” “cancer hormonal mechanisms,” “cancer
61 treatments,” “cancer,” “chemobrain,” “chemofog,”
62 “chemotherapy,” “cognition,” “cognitive changes,” “cognitive
63 effect,” “cognitive impairment,” “depression,” “extracranial
64 cancer,” “inflammation,” “medical decision-making,”
65 “negative emotions,” “neuroendocrinologic,” “neuroimmu-
66 nologic,” “non brain tumors,” “pancreatic cancer,”
67 “post-traumatic stress disorder,” “prognosis,” “prostate
68 cancer,” “radiotherapy,” “radiotherapy,” “sickness behavior,”
69 “stress.”
70 Pathogenesis
71 In the absence of any direct brain involvement, cancers
72 may alter its functions through either the induction of a
73 systemic inflammatory response or the action of neural
74 antibodies (see Table 1).
75 A large amount of evidence shows a correlation between
76 cancer and high levels of pro-inflammatory cytokines,
77 suggesting a link between depressive symptoms in cancer
78 patients and their inflammatory status.1–3 In animal
79 models, depressive-like symptoms were induced by pro-
80 inflammatory cytokines: the administration of IL-1β or
81 TNF-α to rats and mice induced dose- and time-dependent
82 behavioral disturbances (decreased motor activity, social
83withdrawal, anorexia, increased slow-wave sleep, cognitive
84alterations, and increased pain sensitivity).4 Bouchard
85et al 5 examined the relationship between depressive
86symptoms and inflammation in women with early-stage
87breast cancer. They found that depression correlated with
88increased levels of proinflammatory cytokines such as
89IL-1β and IL-6 and, in particular, with higher levels of
90TNF-α. In addition, cytokine administration in patients
91with melanoma frequently induced depressive symptoms,
92including suicidal ideation.6
93An interesting finding was that immune system
94activation resulting from the systemic administration of
95IL-2 and IFN-α to cancer patients decreased plasma
96tryptophan levels, and this reduction correlated with
97the depressive symptoms.7 Decreased tryptophan could
98be due to the activation (mediated by pro inflammatory
99cytokines, including IFN-γ and TNF-α) of enzymes
100involved in tryptophan degradation.8 Since tryptofan
101is the precursor of the neurotransmitter 5-hydroxy-
102tryptamine (serotonin), a decreased tryptophan bioavail-
103ability can lead to decreased serotonin synthesis.
104Increased tryptophan catabolism has been found in
105several malignancies.9–11
106The pathophysiological mechanisms of paraneoplastic
107syndromes have been also associated with the presence of
108either intracellular (anti-Hu, anti-Yo, anti-Ma, and Cv2/
109CRMP5) or neuronal-surface (NMDAR, AMPAR, and
110GABAbR) antibodies.12 In the first case, because the targets
111are deeply located within cells, is thought that T-cell
112cytotoxicity is a key mechanism underlying the neuronal
TABLE 1. Pathogenetic mechanisms for cognitive and behavioral dysfunction in patients with cancer
Proposed pathogenetic
mechanism
References Primary disease
(worldwide incidence as a
percentage of all the tumors)
Molecular mechanism Number of cases (% of
cognitive or behavioral
impairment)
Symptoms and clinical
syndromes
Pro-inflammatorycytokines 13
5
Lung (12.9%)
Breast (11.9%)
Il-6, TNF-α (sputum)
Il-1β, Il-6, TNF-α (blood)
64 (39%)
89 (40%)
Major depression
Plasma tryptophan
(via kynurenic pathway)
14
15
Pancreas (2.4%)
Breast (11.9%)
kynurenic/tryptophan ratio 17 (100%)
80 (36%)
Major depression
Paraneoplastic syndromes
Intracellular antibodies 16‐18 SCLC Anti-Hu 16 (87%)
Case report
Case report
Dementia, confusion,
hallucinations, limbic
encephalitis
19 TGCT (0.4%), Lung cancer*
Other§
Anti-Ma2 18 (100%)
7 (100%)
9 (100%)
8 (100%)
Limbic, diencephalic, or
brainstem
encephalopathy
Neural surface antibodies 20 Ovarian cancer (1.7%)
SCLC
Anti-NMDAR
GABA(b)R and AMPAR
13 (5 of whom with cancer) Limbic encephalopathy
Limbic encephalopathy
Hormonal mechanisms 21 Pancreas (2.4%) Il-6 over-expression, blockage
of serotonin receptors
46 (76%)
115 (12%)‡
Depression
SCLC: small cell lung cancer; TGCT: testicular germ cell tumor;
* adenocarcinoma, large-cell carcinoma, and pleural metastasis of adenocarcinoma;
§ breast, parotid gland, ovary, colon, kidney, lymphoma, and extragonadalchoriocarcinoma;
‡ patients who developed pancreatic cancer following the mental illness designation). Incidence is in accordance with data reported by GLOBOCAN 2012.22
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113 loss.23,24 Clinically, these syndromes share common
114 psychiatric manifestations, ranging from short-term mem-
115 ory impairment to depression and hallucinations.25
116 From a cognitive and behavioral point of view, the
117 most paradigmatic and well-known condition is anti-N-
118 methyl-D-aspartate receptor (anti-NMDAR) encepha-
119 lites. Anti-NMDAR antibodies were first demonstrated
120 in young women with ovarian cancers (eg, teratoma) but
121 have also been identified in patients of both sexes
122 without neoplastic disorders.26 Depletion of NMDAR
123 has dramatic effects on dopaminergic and cholinergic
124 systems, thus leading to autonomic instability and on the
125 ponto-medullary respiratory network, ultimately result-
126 ing in hypoventilation.27,28 More importantly, as a
127 prominent result of the GABAergic dysfunction, patients
128 develop a frontostriatal syndrome with anxiety, mania,
129 paranoia, social withdrawal, and stereotypical behavior
130 (echolalia, echopraxia), in accordance with the so-called
131 “NMDAR theory of schizophrenia.”29,30
132 Hormonal mechanisms might also play an important
133 role in the development of depressive symptoms in
134 cancer patients. For instance, pro-inflammatory cyto-
135 kines are able to trigger the activation of the HPA axis by
136 increasing the level of CRH and vasopressin31,32 and to
137 induce, in periphery, the glucocorticoid receptor resis-
138 tance33 and the abolition of the inhibitory effect of
139 glucocorticoids on cytochine production.34
140 Along this view, an intriguing and less known body of
141 research concerns the association betweenpancreatic cancer
142 and alterations in mood possibly due to multiple mechan-
143 isms.35 Depression, anxiety, and suicidal thoughts often
144 precede or accompany the diagnosis. Moreover, depression
145 often occurs before clinical diagnosis; in addition, in later
146 stages of disease, mood disorders are more pronounced in
147 patients with pancreatic cancer than in those with other
148 abdominal tumors.21,36 However, the pathophysiology of
149 this correlation remains largely unknown, possibly compris-
150 ing tumor-induced changes in the neuroendocrine and acid–
151 base systems.37 In particular, IL-6 over-expression that is
152 induced by pancreatic cancer is known to down-regulate the
153 synthesis of dopamine and norepinephrine, thus interfering
154 with theHPA axis. In addition, pancreatic cancer cellsmight
155 secrete antibodies that directly block serotonin receptors or
156 reduce their synaptic availability in the central nervous
157 system (CNS).38,39
158 Neuroimaging
159 Morphological magnetic resonance imaging (MRI) is
160 normal in most cases, with the exception of anti-NMDAR
161 encephalitis, for which approximately 50% of patients
162 show T2 or FLAIR signal hyperintensity in the hippo-
163 campus, cerebellar or cerebral cortex, frontobasal and
164 insular regions, and, occasionally, the spinal cord.
165 The findings are usually mild or transient and can be
166 accompanied by contrast enhancement in the meninges.28
167In depressed patients with cancer, brain increased
168inflammation, as reflected by plasma C-reactive protein
169and inflammatory cytokine levels, was associated with
170decreased brain connectivity studied with MRI within
171reward-related brain regions.40 Therefore, cancer-induced
172inflammatory status might induce decreased motivation,
173anhedonia, and psychomotor slowing, which are common in
174depressive syndromes. Furthermore, in breast cancer
175survivors, a resting state connectivity MRI study showed
176that fatigued patients exhibited greater connectivity between
177the inferior parietal lobule (IPL) and superior frontal gyrus
178(SFG), and between the medial prefrontal area and the IPL,
179and the degree of this increased connectivity was positively
180correlated with fatigue score, indicating an altered response
181of the resting state network to internal sensory input in
182fatigued subjects.41 In the same patients, functional
183connectivity in the dorsal attention network decreases
184at 1 month and recovers 1 year after chemotherapy (CT)
185treatment in breast cancer survivors (Figure 1).
186Using proton magnetic resonance spectroscopy,
187differences in brain metabolites were shown in the
188posterior insula between fatigued and non-fatigued
189breast cancer survivors.42
190In another interesting study, patients affected by lung
191cancer before treatment demonstrated an alteration of
192glutamate concentration in the occipital cortex.43 The
193relevance of this observation stands in the demonstra-
194tion of an alteration of brain metabolism in cancer
195patients even before treatment.
196Cognitive Changes
197Cancer-related cognitive impairment is observed in severe,
198subacute clinical conditions (such as immune-mediated
199encephalitis or vitamin deficiency encephalopathy), or in
200chronic forms of cognitive decline (see Table 2).
FIGURE 1. Possible pathophysiological mechanisms underlying cognitive and
behavioral changes in patients with cancer.
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201 Paraneoplastic limbic encephalitis44 is characterized by
202 a subacute (days to several weeks) appearance of confusion
203 and memory loss with an inability to remember new
204 information due to dysfunction of the mesial temporal lobe
205 (particularly the hippocampus), behavioral changes, and
206 psychiatric symptoms (including depression, agitation and
207 psychosis, aggression, and compulsive behavior); the latter
208 symptoms are very common and often predominate,
209 especially during the early stages of disease. Altered
210 cognition may fluctuate, and the level of consciousness
211 often declines progressively to coma. Recurrent temporal
212 seizures are frequent and sometimes progress to status
213 epilepticus. When neuronal damage derives from inflam-
214 mation and necrosis (classic limbic encephalitis with
215 intracellular antibodies), prognosis is usually poor and
216 depends on the extension of cerebral lesions; on the
217 contrary, synaptic interference mediated by cell-surface
218 antibodies is reversible so that neuronal damage is limited
219 and, if treated, anti-NMDA encephalitis has generally a
220 better outcome.46
221 Wernicke’s encephalopathy is a severe neuropsychiatric
222 syndrome due to thiamine (Vitamin B1) deficiency, usually
223 observed in malnourished alcoholics. It is characterized by
224 a triad of signs including eye movement disorders,
225 cerebellar dysfunctions (ataxia or gait instability), and
226 altered mental status. Disorientation in time and space,
227 confusion, impaired memory, and decreased attention are
228 often described, sometimes evolving to severe and irrever-
229 sible memory deficit with confabulation (Korsakoff’s
230 syndrome). Cancer patients are at risk of vitamin
231 deficiency for many reasons: thiamine intake could be
232 insufficient due to malnutrition, nausea, vomiting, or
233 prolonged parenteral nutrition; gastrointestinal surgery
234 may induce malabsorption through the loss gastrointest-
235 inal surface.47 A prompt administration of thiamine can
236 lead to excellent clinical improvement.
237Estimates vary widely regarding the number of
238patients who suffer cognitive impairment during the
239course of the cancer depending on the tissue affected;
240studies have reported cognitive dysfunction frequencies
241of 13%–70% in patients after treatment.48,49 Indeed,
242cognitive disorders (observed in up to 75%) appear
243during treatment and decrease after treatment (by up to
24460%). Also, some patients (approximately 40%) exhibit
245cognitive impairment even before treatment.50 The risk
246of cognitive impairment is approximately 3.5 times
247higher in treated (with chemotherapy) women affected
248by breast cancer than in untreated patients.51 In most
249studies, the effect of cancer therapy was studied for a
250relatively short period (1–2 years post treatment);
251however, cognitive changes in long-term survivors are
252predictable. Although long-term post-treatment cogni-
253tive changes persist only in a minority (17–34%) of
254cancer survivors,52 cross-sectional studies indicate that
255after therapy (up to 20 years) patients continue to exhibit
256worse cognitive performance than non-cancer controls.53
257Neuropsychological assessment
258Cognitive impairment affects memory and attention.
259Specifically, patients have difficulties in learning new
260information and remembering appointments, and exhibit
261an enhanced forgetfulness that can interfere with key daily
262living activities. An impairment in executive function also
263occurs, such as difficulties in planning daily programs or
264implementing strategies that require mental flexibility to
265cope with future needs and unforeseen events. This type of
266memory and attention complication is indicative of a
267frontal-subcortical profile54 and is suggestive of diffuse
268brain dysfunction.55
269Although cognitive impairment in oncological
270patients has been measured using a variety of tests, the
TABLE 2. Cancer-related cognitive syndromes
Syndrome Onset Clinical features (symptoms and signs) Diagnostic tools Outcome
Neuropsychiatric Neurological
Limbic encephalitis
(antibodies to intracellular
antigens)
Acute-subacute Confusion/disorientation,
behavioral changes, psychiatric
symptoms milder than cognitive
impairment
Seizures, decrease level of
consciousness, coma, headache,
sleep disorder, ataxia, movement
disorders
Brain MRI, EEG, cerebrospinal
fluid (CFS) analysis, serum
and CFS autoantibodies
Neuropsychology examination
Generally poor
Anti NMDA encephalitis
(antibodies to neuronal cell
surface antigens)
Acute-subacute Confusion/disorientation,
behavioral changes, cognitive
impairment milder than psychiatric
symptoms
Generally good
Nutritional deficiency
encephalopathy (Wernicke’s
syndrome)
Subacute Confusion/disorientation, memory
loss with confabulations
Ophtalmoparesis, ataxia Brain MRI, serum thiamine level,
neuropsychological examination
Good if promptly
treated
Mild cognitive impairment
(chemo brain)
Chronic Preeminent memory and executive
function impairment
Nonspecific Neuropsychological examination Variable
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271 affected domains are consistent: processing speed, execu-
272 tive function, and working memory are most strongly
273 affected.56 An issue that is often discussed in cancer-
274 related cognition assessment is whether cognitive
275 impairments are better measured using self-reporting
276 questionnaires or objective neuropsychological testing.
277 Perceived cognitive impairment (PCI) is one of the most
278 prevalent symptoms, and accurate subjective reports of
279 cognitive impairment might be useful.56 The Interna-
280 tional Cognition and Cancer Task Force57 suggested a
281 core battery test that can identify the domains that are
282 mainly affected: the Hopkins Verbal Learning Test-
283 Revised (HVLT-R) to test learning and memory, the Trail
284 Making Test (TMT) to test executive function and
285 attention, and the Controlled Oral Word Association of
286 the Multilingual Aphasia Examination to measure the
287 speed of lexical fluency. The authors added that this basic
288 examination could be completed by additional tests of
289 working memory.
290 Management
291 Although modafinil and methylphenidate can improve
292 cognition, they have side-effects. Donepezil has been
293 also tested in cancer patients with cognitive impair-
294 ment.58 Small improvements were described, but these
295 findings require confirmation using larger and more
296 conclusive trials.
297 Nonpharmacological approaches enhance cognitive
298 performance and perceived cognitive functioning.59
299 Rehabilitation programs include direct cognitive rehabi-
300 litation or compensatory training that addresses execu-
301 tive functioning and attention, processing speed,
302 working and long-term memory, and visual-spatial skills.
303 Most studies have shown significant improvements in
304 objective and subjective cognitive performance and in
305 quality of life in patients undergoing rehabilitation.
306 Treated patients also showed better improvement in
307 non-trained skills and better managed other psychologi-
308 cal symptoms, such as anxiety, depression, and fatigue,
309 and improved sleep quality.60 Cognitive training appears
310 to be the most effective for groups and individuals.59
311 However, coping strategies such as cognitive-behavioral
312 therapy (CBT)60 or restorative and mindfulness-based
313 stress reduction programs61 have been proposed to
314 improve cognitive functions, and encouraging results
315 emerged. Some improvements were reported with
316 physical exercise62 and yoga practice,63 but these studies
317 involved small sample sizes and different types of
318 exercise programs.
319 Affective and Behavioral Changes
320 Patients with cancer are particularly vulnerable to the
321 development of behavioral alterations and psychiatric
322disorders, which may in turn affect the course and
323outcome of the primary oncologic disease.64 Therefore,
324to implement the appropriate therapeutic intervention,
325it is important to establish a psychopathological
326diagnosis by differentiating expected emotional reac-
327tions from isolated symptoms (eg, anger or irritability)
328and syndromes (eg, adjustment disorders or major
329depressive disorder).
330Several factors need to be considered regarding the
331etiology and pathophysiology of the behavioral altera-
332tions and psychiatric disorders that occur after cancer
333diagnosis. For instance, the stress, diagnosis, and
334treatment of cancer may cause substantial psychiatric
335morbidity. From a symptomatic perspective, moreover,
336acute anxiety, depression with despair, agitation, irrit-
337ability, poor therapeutic adherence, anger, and sleep
338disturbances may be linked with the emotional and
339behavioral dimensions of pain.65 In addition, there are
340established risk factors for affective disorders and
341behavioral alterations after cancer diagnosis. These may
342be related to the cancer (eg, advanced cancers, certain
343types of cancer, being physically weakened by cancer) or
344not (eg, having a personal history or a positive family
345history of mental disorders, being unmarried). Finally,
346family members and caregivers of patients with cancers
347are also at higher risk for the development of behavioral
348alterations and mental disorders.
349Although the Diagnostic and Statistical Manual of
350Mental Disorders, Fifth Edition acknowledges the
351possibility of diagnosing several types of mental dis-
352orders in patients suffering from cancer, the most
353frequently reported conditions are depressive, anxiety,
354trauma-, and stressor-related disorders66,67 (see Figure 2
355and Table 3). Such conditions can occur at different
356stages of the illness: when patients receive the diagnosis,
357when they initiate treatment, and after they achieve
358remission.68
359Prevalence rates of depression in cancer patients
360ranging from 8% to 25%69,70 have been reported. In a
361recent meta-analytic investigation, Mitchell et al 66
362included 24 studies involving 4007 patients across seven
363countries in palliative-care settings. The pooled preva-
364lence of depressive disorders, as identified through DSM
365or ICD criteria, was 16.5% (14.3% major depression and
3669.6% minor depression); the prevalence of adjustment
367disorder was 15.4%, and the prevalence of anxiety
368disorders was 9.8%. Co-occurring diagnoses were
369common. All types of depression were found to occur in
37020.7%, depression or adjustment disorder in 31.6%, and
371any mood disorder in 38.2% of the patients.66 Notably,
372adjustment disorder with depressed and/or anxious
373mood was the most common diagnosis (68%).71
374Another distinct syndrome to take into consideration
375when assessing depression is demoralization, which has
376been described as a specific and different condition of
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377 existential distress in individuals at the end of their life.
378 Patients describe feelings of hopelessness and/or help-
379 lessness, which are often related to the experience of a
380 loss of meaning in life. Certain symptoms may overlap
381 with major depression. Demoralization in the medically
382 ill population recently showed prevalence rates ranging
383 from 20.6% to 33.3% of cases.72 Anxiety disorders have
384 been variably associated with the diagnosis and treat-
385 ment of cancer, and their prevalence can paradoxically
386 increase after the treatment of cancer is concluded,
387 because patients may feel more vulnerable.73 The
388 prevalence of posttraumatic stress disorder (PTSD) in
389 cancer patients ranges from 5% to 19%.74
390 The lifetime prevalence rates of affective disorders
391 in patients with ovarian and prostate cancers in pre-,
392 during-, and post-treatment settings range from 8% to
393 27%.75,76 Patients with head and neck cancer were found
394 to show the highest rates of major depressive disorder
395 among oncological patients, with an incidence of
396 15%–50%.77 Previously, depression has been strongly
397 associated with oropharyngeal (22%–57%), pancreatic
398 (33%–50%), breast (1.5%–46%), and lung (11%–44%)
399 cancer, with lower rates in in patients affected by other
400 forms of cancer, such as colon (13%–25%) and gyneco-
401 logical (12%–23%) cancers and lymphoma (8%–19%).78
402 In terms of prognosis, evidence showing that depression
403 is responsible for significant suffering and distress, reduces
404 participation in medical care, and can prolong the hospital
405 stay needs to be particularly taken into account.79,80
406 The suicide incidence in cancer was found to be
407 approximately double that in the general population.81
408 Diagnoses specifically associated with higher suicide
409 rates include prostate, lung, pancreatic, head, and neck
410 cancers, with the first year after diagnosis carrying a
411 higher risk for suicide.81,82
412 Management
413 Though the treatment of major depression and other
414 comorbid psychiatric disorders improves the quality of
415life in patients with cancer, fewer than half of patients
416receive psychopharmacological treatment.67,83
417In addition, the treatment of depression has proven to
418increase patient satisfaction with oncologic treatments and
419related compliance.84 Recommendations on the use of
420psychotropic medications in oncologic patients have been
421formulated by dedicated task forces and guidelines are
422available.85,86 The efficacy of antidepressants in oncology
423is well established on the basis of randomized, controlled
424studies.87–89 Thekdi et al 90 reported that selective seroto-
425nin reuptake inhibitors (SSRIs) represent the first choice
426for the treatment of depression and generalized anxiety
427and the prevention of panic attacks in cancer patient.90
428Benzodiazepines are considered well-tolerated, safe, and
429effective treatments in the short-term, although their long-
430term use can induce tolerance and reduced efficacy.90
431Other antidepressants, such asmirtazapine and bupropion,
432were found to effectively target not only depression and
433anxiety but also symptoms like sleep alterations, nausea,
434anorexia, fatigue, reduced concentration, and nicotine
435dependence, even though their tolerability in patients with
436anxiety may be problematic.91,92 Several drugs are helpful
437for the adjuvant treatment of cancer-related symptoms,
438such as, for instance, psychostimulants for fatigue.93
439Benzodiazepines are particularly useful for the treatment
440of insomnia and, when combined with anti-emetics, were
441found to relieve chemotherapy-induced nausea and vomit-
442ing.94 Neuropathic pain may benefit from adjuvant
443treatment with selective serotonin norepinephrine reup-
444take inhibitors (SNRIs), low-dose tricyclic antidepressants,
445and SSRIs.95,96 An effective psychopharmacological inte-
446grated treatment is mandatory in cancer patients given the
447evidence that untreated psychiatric comorbidity is asso-
448ciated with higher disability, poorer quality of life, and
449reduced adherence to cancer treatment.97
450If, on one hand, different psychopharmacological
451treatments can be effective in ameliorating various
452cancer-related psychiatric symptoms, on the other hand,
453some commonly used psychotropics can interfere with the
454progression of specific forms of cancer and with the action
FIGURE 2. Functional connectivity in the dorsal attention network (premotor cortex, cuneus, and putamen) decreases at 1 month (A) and recovers 1 year after
chemotherapy treatment (B) in breast cancer survivors (averaged images; modified from Dumas et al 139, with permission).
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TABLE 3. Affective and behavioral disorders in patients with cancer
References Design Cancer type (worldwide
incidence as a percentage
of all the tumors)
Affective and
behavioral
disorder
Prevalence Diagnostic tools Treatment
71 Research investigation Various Adjustment Disorder 68% DSM III, SCL-90-R, RDS, GAIS, KPS Unspecified
66 Meta-analysis Various Depression;
Adjustment disorder;
Anxiety
24%
15.4%
9.8%
Standardized criteria and semi-structured interviews Unspecified
69 Review Various Depression 20–25% MMPI, DSM-III, HAD, PSE, BDI, BSI, GHQ Psychological, pharmacological
interventions, or a combination
77 Review Head and neck cancer (3%) Depression 15–50% Unspecified Pharmacological, social, and
psychological interventions
70 Meta-analysis Various Depression 8–24% HADS depression subscale, CES-D, BDI Unspecified
75 Meta-analysis Prostate cancer (7.8%) Depression
Anxiety
Pretreatment 17.27%, on-treatment
14.70%, post-treatment 18.44%
Pretreatment 27.04%, on-treatment
15.09%, post-treatment 18.49%
HADS, STAI, CES-D, SCL, BDI, SRAS, SRDS, BSI, CIDI
Anxiety Scale for Prostate Cancer and the Effects of Prostate
Cancer on Lifestyle Questionnaire.
Unspecified
76 Meta-analysis Ovarian cancer (1.7%) Depression
Anxiety
Pretreatment 25.34%, on-treatment
22.99%, post-treatment 12.71%
Pretreatment 19.12%, on-treatment
26.23%, post-treatment 27.09%
HADS, STAI, CES-D, SCL, BDI, SRAS, SRDS, BSI, CIDI,
and DSM-IV-SCID
Unspecified
78 Review Various Depression 0–38% HADS, BDI, European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire, and DSM criteria
Antidepressants
72 Review Various Demoralization syndrome 13–18% DS, DCPR Antidepressants and psychotherapy
(depression comorbidity)
74 Review Various Posttraumatic stress
disorder
5–19% PCL-C and semi-structured interviews Psychological, pharmacological
interventions or a combination
BDI: Beck Depression Inventory; BSI: Brief Symptom Inventory; CES-D: Center for Epidemiologic Studies-Depression Scale; CIDI: Composite International Diagnostic Interview; DCPR: Diagnostic Criteria for Psychosomatic Research; DS: Demoralization Scale; DSM-III,
Diagnostic and Statistical Manual for Disorders, version 3 (Interview assessment); GAIS: Global Adjustment to illness Scale;GHQ: General Health Questionnaire; HAD: Hospital Anxiety and Depression Scale; HADS: Hospital Anxiety and Depression Scale-depression
subscale; KPS:Karnofsky performance scale; MMPI: Minnesota Multiphase Personality Inventory; PCL-C: PTSD (Posttraumatic Stress Disorder) Checklist Civilian Version; PSE: Present State Examination; RDS: Raskin Depression screen; SCID: Structured Clinical Interview
for DSM; SCL: Symptom Checklist; SRAS: Self-Rating Anxiety Scale; SRDS: Self-Rating Depression Scale; STAI: State-Trait Anxiety Scale. Incidence is in accordance with data reported by GLOBOCAN 2012.22
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455 of certain antineoplastic drugs. Among the former, for
456 instance, several antipsychotics were shown to increase
457 serum prolactin, and hyperprolactinemia has been linked,
458 in turn, to the development of mammary gland tumors in
459 animal studies.98 If, in these cases, second generation
460 antipsychotics should be preferred to neuroleptics, none-
461 theless, more studies and updated recommendations from
462 treatment guidelines are needed to assess pros and cons of
463 undertreatment of serious psychiatric disorders in patients
464 with cancer, based on unproven contraindications to
465 psychiatric medications.99
466 Another noteworthy issue is represented by the
467 interaction that some antineoplastic drugs may have
468 with psychotropic drugs that interfere with cytocrome
469 P450 (CYP). One of the most studied cases in the field is
470 represented by tamoxifen, an adjuvant hormonal therapy
471 that is widely used for estrogen receptor positive
472 metastatic breast cancer. Given that tamoxifen is
473 metabolized to its more active form (endoxifen) by
474 CYP2D6, decreases in CYP2D6 activity due to interac-
475 tions with psychotropic drugs that inhibit it
476 (eg, paroxetine and fluoxetine) may reduce the activity
477 of tamoxifen and confer an increased risk of recur-
478 rence.100 If, in such contexts, psychotropic drugs that
479 do not interfere with the activity of CYP2D6 should
480 be preferred, recent data in the field have assessed the
481 available evidence in a more balanced way,101 recom-
482 mending caution and considering clinical aspects that
483 vary from case to case.
484 Over the last several years, novel approaches for the
485 management of behavioral alterations in patients with
486 cancer have been proposed and examined. Among these,
487 ketamine—a dissociative anesthetic psychotropic com-
488 pound—has been tested in oncologic patients with
489treatment-resistant depression102,103 and suicidal idea-
490tion104 with encouraging results. As for non-oncologic
491psychiatric patients, however, it remains to be further
492clarified whether the role of ketamine is maintained
493beyond the short-term. Other authors have hypothesized
494that brain stimulation techniques, particularly non-
495invasive interventions like repetitive transcranial mag-
496netic stimulation (rTMS) and transcranial direct current
497stimulation (tDCS), might be helpful for patients with
498cancer and psychiatric symptoms in light of their
499selective action, lack of systemic effects, and no interac-
500tion with concomitant antineoplastic drugs. However, no
501controlled investigation is currently available to endorse
502an approach of this kind.
503Chemotherapy- and Radiotherapy-Induced
504Disturbances
505Several studies have shown chemotherapy-related cogni-
506tive dysfunction (see Table 4). The design of these studies
507was mainly cross sectional: the cognitive function of
508treated patients was compared with matched controls,
509and the identification of significant cognitive impair-
510ments in the chemotherapy groups addressed the
511pathogenetic role of cytotoxic agents.48,49,51,55,105,106
512Although such studies were fundamental to validating
513the cognitive complaints of cancer patients, they did not
514control for confounding factors. Yet, cancer patients may
515complain of cognitive symptoms before any treatment.
516Consequently, more recently the study design changed;
517dismissing a cross-sectional experimental design, pro-
518spective studies were conducted. Regardless of the study
519design used, breast cancer patients who were treated
TABLE 4. Chemo- and radiotherapy-associated cognitive impairment
Therapy References Primary disease Symptoms and clinical syndromes Dose of radiation
Chemotherapy (CT)
FAC 50, 104, 117 Breast Attention, processing speed, learning, memory,
executive and visuospatial function, motor skills
FEC or CTC 118 Breast Attention, working, visual and verbal memory,
executive and visuospatial function, motor skills
FEC, DCP or DC 119 Breast Attention, working, visual, and verbal memory
AAT 37, 113-115 Prostate Visual and visuospatial memory and processing,
reaction time, working memory
Radiotherapy (RT)
120
121
122
123
Neck
rhabdomyosarcoma
Breast
Breast§
Breast
Mild cognitive impairment (only in 20%)
Attention, complex cognition
Executive functions, processing speed
Verbal memory
4,140-6,500 cGy at tumor site; 3,000
cGy for the whole brain
Not reported
50 Gy tangential irradiation
Mean dose ≈ 5900-6000
(±600) cGy
FAC: 5-fluorouracil, doxorubicin, and cyclophosphamide; FEC: 5-fluorouracil, epirubicin, and cyclophosphamide; CTC: cyclophosphamide, thiotepa, and carboplatin;
DCP: doxorubicin, cyclophosphamide, and paclitaxel; AAT: androgen ablation therapy; § RT in combination with CT.
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520 with cytotoxic agents showed a cognitive decline relative
521 to their pre-treatment cognitive status and to breast
522 cancer patients without chemotherapy and non-cancer
523 controls over the same period.54,55,107,108 Specific drugs
524 may have different effects. Fluorouracil can induce
525 hyperammonemia,109 thus causing hyperammonemic
526 encephalopathy, whose clinical manifestations range
527 from psychomotor slowing and flapping tremor to
528 severe consciousness disturbances.110 Also, luteinizing
529 hormone-releasing hormone (LHRH) agonists are asso-
530 ciated with non-nonsteroidal antiandrogens to obtain a
531 combined androgen blockage,111,112 and this treatment
532 can cause neurological disturbances such as visuomotor
533 slowing, slowed reaction times, and impaired working
534 memory.113–115
535 Several trials found a correlation between cognitive
536 dysfunction and chemotherapy in women with non-
537 metastatic breast tumors.48,50,105,106,116 This association
538 is termed “chemobrain.” In women receiving a regimen of
539 5-fluorouracil, doxorubicin, and cyclophosphamide, Wefel
540 et al50 showed that approximately 60% of patients
541 experienced a cognitive decline with decreased attention,
542 learning, and processing speed, thus suggesting a disrup-
543 tion in frontal network systems. Interestingly, many
544 patients improved 1 year after completing 5-fluorouracil,
545 doxorubicin, and cyclophosphamide (FAC) therapy,
546 especially when work-related abilities were tested. In this
547 context, it is worth noting that before the initiation of
548 systemic adjuvant therapy, women with breast cancer
549 exhibited declines in a wide range of cognitive functions,
550 involving verbal learning, nonverbal memory, confronta-
551 tional naming, complex visuoconstruction, and fine motor
552 dexterity.116 Women treated with tamoxifen for breast
553 cancer have lower brain concentrations of myo-inositol.124
554 Tamoxifen induces areas of hypometabolism in the inferior
555 and dorsal lateral frontal lobes and decreases right
556 hippocampal volumes.125
557 The irradiation of head and neck tumors (in particular
558 cancer of the nasopharynx and paranasal sinuses)
559 might cause radiation-induced vascular damage in the
560 medial temporal lobe, thus affecting memory. Irradiation
561 triggers an inflammatory response with endothelial
562 injury.126 Paulino et al120 reported intellectual and
563 academic delays in 3 out of 30 children who had received
564 megavoltage radiotherapy for head and neck rhabdomyo-
565 sarcoma. A moderate general developmental delay
566 including pronounced motor deficits that were asso-
567 ciated with various levels of perceptual and cognitive
568 problems was observed in all children treated with total
569 brain irradiation prior to bone marrow transplanta-
570 tion.127 Cognitive impairment accompanying radiother-
571 apy has also been reported after the irradiation of body
572 regions that are distant from the brain, in particular for
573 non-metastatic breast cancer treatment,121,122,128,129
574 possibly by increasing levels of IL-6.123 Radiation dose,
575site of primary tumor, and the timing of association with
576chemotherapy (CT) are variable (Table 4), and further
577studies are needed to assess possible cognitive and
578behavioral effects induced by tissues irradiation. Overall,
579while CT has a specific negative effect on verbal fluency,
580breast cancer treatment in general negatively affects verbal
581memory. However, cognitive impairment induced by either
582CT or radiation therapy is probably mild, and difficult to
583disentangle from that due to primary disease.
584Relevance of Neuropsychopathological Abnormalities
585for the Clinical Outcome
586Depressive symptoms and psychosocial stressors can be
587considered risk factors for cancer incidence and mortal-
588ity by affecting several neuroimmunological and neu-
589roendocrinological biochemical pathways.130–132 When
590a potentially risky event is perceived by the subject as
591overwhelming the available resources (such as coping
592strategies and social support), the nervous system
593activates pathways that release catecholamines, cortico-
594steroids, and opioids.133 Because the receptors for these
595chemical signals (neurotransmitters, neuropeptides,
596neurohormones, and adrenal hormones) are also located
597on lymphocytes and macrophages, the release of these
598cerebral messengers can influence immune and endo-
599crine functionality (see Figure 3) in vivo and in vitro.134
600Through these mechanisms the brain exerts an immu-
601noregulatory role in oncologic diseases.135 For example,
602the plasma concentration of epinephrine, which is
603associated with intense emotions, especially fear, is
604inversely related to specific immune functions in lympho-
605cytes and monocytes. The experience of stressful events is
606concomitant with the release of high concentrations of
607corticosteroids that have important immunosuppressive
608effects on the functions of lymphocytes and macrophages
609and might affect their circulation patterns.136,137
610In this context, psychological interventions during
611oncologic treatments are important resources that aim to
612improve psychological conditions and therefore revert
FIGURE 3. The interactions between psychological aspects, the CNS, and the
endocrine and immune systems.
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613 dysfunctional immunological and endocrinal mechanisms
614 with consequent positive effects on the disease. Studies
615 have reported the improvement of immunologic para-
616 meters (eg, lymphocyte proliferation138 and their related
617 physiologic values (eg, cortisol levels) in patients who
618 attended psychological support sessions.139 Andersen
619 et al140 examined the influences of a psychosocial
620 treatment on survival and recurrence (227 women with
621 non-metastatic breast cancer) immediately after surgery.
622 Psychological intervention included training for relaxation
623 and stress reduction, coping skills implementation, and
624 strategies to change health behavior related to nutrition
625 and physical activity. The treatment group showed a
626 significant decrease in overall and breast cancer–specific
627 mortality rates, and the risk of cancer recurrence was
628 reduced by 45% at a median of 11 years follow-up.140
629 Studies on cancer survivors have emphasized the
630 role of positive emotions, resilience, and optimism
631 in contributing to better adjustment and quality of
632 life.141,142 Empirical evidence has shown that these
633 protective psychological factors predict better coping
634 among cancer patients.143,144
635 Because stress impacts on neuroendocrine and neu-
636 roimmunological mechanisms influencing tumor onset,
637 progression, and recurrence (eg, ovarian cancer),145
638 psychosocial and psychoeducational interventions must
639 be considered an integral part of cancer treatment.
640 The integrity of cognitive aspects (such as attention,
641 perception, and thought) may indirectly influence cancer
642 incidence and progression from pre-clinical conditions.
643 For example, conditions of depression and distress may
644 impact on perceptions of risk and on decision-making
645 strategies146 leading to the adoption of risky behaviors
646 (such as smoking, alcohol and drug consumption), which
647 in turn could cause immunological and endocrinal
648 changes.147 Moreover, a condition of distress and a bad
649 patient–physician relationship has been shown to influ-
650 ence adherence to medical prescription148 and to
651 interfere with attendance at screening procedures
652 (such as mammography) and with active surveillance of
653 tumors with low metastatic potential.149 In conclusion,
654 making decisions, especially about healthcare, is not
655 a linear process; patients’ viewpoints are influenced
656 by cognitive (eg, biases and heuristics) and emotional
657 factors (eg, intense emotional expressions), which
658 modulate the presentation and interpretation of medical
659 information.150 It is extremely important that patients
660 are supported in order to not succumb to cognitive biases
661 and to allocate attention efficiently to improve compre-
662 hension and make optimal decisions.151
663 Clinical Implications
664 Cancer can induce neuropsychological and behavioral
abnormalities through different mechanisms, with
665several practical implications. First, every patient report-
666ing an abrupt onset of mood or cognitive dysfunction
667without a clear hereditary predisposition or other
668immediately evident environmental or medical cause
669should be screened also for the possible presence of
670cancer. Similarly, patients affected by a chronic psychia-
671tric disorder exhibiting a sudden change of their
672psychopathological or cognitive picture should be
673screened for cancer also. Yet, as discussed above, several
674tumors may appear as mild cognitive or psychiatric
675disturbances months before they become manifest.
676Second, clinicians should bear in mind that the
677decision-making capacity in patients with cancer can be
678impaired, yielding forensic implications. Finally, but
679perhaps most importantly, the data reviewed above
680indicated the importance of interventions that aim to
681restore normal cognitive and behavioral conditions.
682Because psychological and cognitive wellness impor-
683tantly contribute to the quality of life in patients with
684cancer, clinicians, in addition to treating the primary
685manifestation of cancer, should always carefully search
686for and treat cognitive and mood abnormalities.
687Although there are no systematic data, our experience
688is that patients undergoing chemotherapy should be
689carefully evaluated for their driving ability.
690We therefore propose that every patient accessing a
691cancer hospital should be formally screened for cogni-
692tive, psychiatric, or psychological abnormalities that, if
693present, should be immediately treated. To ensure this,
694a multidisciplinary team comprising neurologists,
695psychiatrists, neuropsychologists, and psychologists is
696recommended in all cancer centers.
697Future Directions
698It is fundamental to expand our frame of reference to
699explore the neurobiological activities that have been
700related to stress factors and other psycho-social phenom-
701ena which may operate in concert with stress-related
702neuroimmunologic and neuroendocrinologic changes in
703influencing disease outcomes. Future challenges consist
704in demonstrating how psychological processes and
705interventions influence tumor environmental complex-
706ity through underlying mechanisms mediated by stress
707and negative emotionality and related to the clinical
708course of disease. To understand these phenomena in
709depth, new study designs and consequent paradigms of
710cure should be tested.
711First, it could be useful to develop a translational
712human-animal design to investigate specific targets of
713tumorigenic activity determined by stress using a murine
714model. Moreover, in everyday clinical practice a new
715therapeutic approach, which encompasses a stronger
716neuro-psycho-oncological intervention, should be
717adopted. As already demonstrated by previous research,
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718 stress management interventions for cancer patients
719 have promising effects on psychological aspects, tumor-
720 related factors, and prognosis and should be included
721 in oncologic routine care. Future study designs should
722 focus on ameliorating psychological treatment and
723 support during the management of the oncologic
724 disease. This endpoint could be achieved through the
725 personalization of interventions, which, according to the
726 patients’ needs, could include sessions that enhance
727 decision-making strategies and/or coping skills. In this
728 framework, the assessment of patients’ cognitive and
729 psycho-emotional factors would be important in order
730 to draw individual profiles and customize treatment.
731 Simple interactive tools (ie, an “app” for cell phones and
732 tablets) to explore patients’ preferences giving immedi-
733 ate feedback (for example about drugs characteristics or
734 side effects) to physicians, and to help patients in every
735 day choices regarding the disease, may constitute a useful
736 and innovative way to face the pathology.
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